Skip to Content

Ligand Pharmaceuticals Inc LGND

Morningstar Rating
$101.55 +2.21 (2.22%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

LGND is trading at a 877% premium.
Price
$99.45
Fair Value
$676.56
Uncertainty
Very High
1-Star Price
$937.65
5-Star Price
$29.88
Economic Moat
Lfrpqp
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LGND is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$99.34
Day Range
$99.47101.60
52-Week Range
$49.28101.92
Bid/Ask
$101.02 / $101.50
Market Cap
$1.82 Bil
Volume/Avg
27,350 / 142,261

Key Statistics

Price/Earnings (Normalized)
21.10
Price/Sales
14.88
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
58

Comparables

Valuation

Metric
LGND
RPTX
FUSN
Price/Earnings (Normalized)
21.10
Price/Book Value
2.200.727.56
Price/Sales
14.881.71772.35
Price/Cash Flow
25.74
Price/Earnings
LGND
RPTX
FUSN

Financial Strength

Metric
LGND
RPTX
FUSN
Quick Ratio
19.038.2210.37
Current Ratio
20.708.3310.64
Interest Coverage
204.37−18.82
Quick Ratio
LGND
RPTX
FUSN

Profitability

Metric
LGND
RPTX
FUSN
Return on Assets (Normalized)
2.84%−8.90%−34.33%
Return on Equity (Normalized)
3.29%−10.92%−45.42%
Return on Invested Capital (Normalized)
2.34%−14.99%−37.43%
Return on Assets
LGND
RPTX
FUSN
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
QxwxkzwdbnTqcb$579.2 Bil
Vertex Pharmaceuticals Inc
VRTX
LxbcpvqdGgbglh$126.0 Bil
Regeneron Pharmaceuticals Inc
REGN
QqwkvxncPqysstq$117.6 Bil
Moderna Inc
MRNA
JztclvnnFwhlg$46.5 Bil
Alnylam Pharmaceuticals Inc
ALNY
PvlpsxlrHbgwnf$29.9 Bil
argenx SE ADR
ARGX
SmfgmcwclRmhb$27.7 Bil
BioNTech SE ADR
BNTX
FnnpdbhcPyjtn$20.8 Bil
Biomarin Pharmaceutical Inc
BMRN
CbnmqhbsHsprvwz$15.8 Bil
United Therapeutics Corp
UTHR
MyyscqstMkpk$14.6 Bil
Incyte Corp
INCY
QtvvxgpjSqnmbc$12.9 Bil

Sponsor Center